Edit |   |
---|---|
Antigenic Specificity | CD19 (Obexelimab biosimilar) |
Clone | monoclonal |
Host Species | Chimeric Human/Mouse |
Reactive Species | human |
Isotype | IgG1 kappa |
Format | Protein A/G purified |
Size | 100 µg, 1 mg, |
Concentration | typically between 0.5-2.0 mg/ml. |
Applications | ELISA, WB |
Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
Description | Obexelimab is a monoclonal antibody biosimilar expressed in CHO cells, targeting CD19, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Obexelimab (XmAb5871) is a first-in-class monoclonal antibody that targets CD19 with its variable domain and uses the XmAb immune inhibitory Fc domain to target Fc?RIIb, a receptor that inhibits B cell function. Obexelimab is the first drug candidate to our knowledge that targets Fc?RIIb inhibition. |
Immunogen | n/a |
Other Names | Obexelimab, CD19, 1690307-05-1 |
Gene, Accession # | CAS: 1690307-05-1 |
Catalog # | abx831323 |
Price | please inquire |
Order / More Info | CD19 (Obexelimab biosimilar) Antibody from ABBEXA LTD |
Product Specific References | n/a |
U.S. Office
118 Eldridge Rd, Suite C,
Sugar Land, TX 77478 USA
Telephone: +1 832 327 7413
Netherlands Office
Abbexa BV
Wattstraat 54 2723 RD,
Zoetermeer,Netherlands
Telephone: +44 (0) 1223 755950